Volume 12 Issue 6
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(6): 676-681
Xu Yue, Hu Xiaopeng. Research progress on desensitization therapy for highly sensitized kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 676-681. doi: 10.3969/j.issn.1674-7445.2021.06.005
Citation: Xu Yue, Hu Xiaopeng. Research progress on desensitization therapy for highly sensitized kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 676-681. doi: 10.3969/j.issn.1674-7445.2021.06.005
shu

Research progress on desensitization therapy for highly sensitized kidney transplant recipients

doi: 10.3969/j.issn.1674-7445.2021.06.005

  • Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

More Information
  • Corresponding author: Hu Xiaopeng, Email: huxp@ccmu.edu.cn
  • Received Date: 2021-09-01
  • Publish Date: 2021-11-15
    Abstract
  • Human leukocyte antigen (HLA) sensitization has been previously considered as a contraindication for kidney transplantation. In the past 30 years, with the development of desensitization therapy strategies and immunosuppressants, more and more highly sensitized patients have been eligible for kidney transplantation. However, highly sensitized patients still face a high incidence of hyperacute rejection and antibody-mediated rejection following kidney transplantation, which restricts the success of kidney transplantation and long-term graft survival. At present, exploring effective desensitization regimen is a hot spot in the research of organ transplantation. In this article, the current desensitization therapy strategies, new preparations for desensitization therapy, and the benefits and risks of desensitization therapy were reviewed, and the current status and future direction of desensitization therapies were investigated, aiming to provide reference for resolving the immune barrier, improving the success rate of kidney transplantation and enhancing the quality of life of highly sensitized recipients.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    AXELROD DA, SCHNITZLER MA, XIAO H, et al. An economic assessment of contemporary kidney transplant practice[J]. Am J Transplant, 2018, 18(5): 1168-1176. DOI: 10.1111/ajt.14702.
    [2]
    黄洁夫. 中国器官移植发展报告(2019)[M]. 北京: 清华大学出版社, 2020.
    [3]
    HART A, LENTINE KL, SMITH JM, et al. OPTN/SRTR 2019 annual data report: kidney[J]. Am J Transplant, 2021, 21(Suppl 2): 21-137. DOI: 10.1111/ajt.16502.
    [4]
    JORDAN SC, CHOI J, KAHWAJI J, et al. Progress in desensitization of the highly HLA sensitized patient[J]. Transplant Proc, 2016, 48(3): 802-805. DOI: 10.1016/j.transproceed.2015.11.027.
    [5]
    CHOI AY, MANOOK M, OLASO D, et al. Emerging new approaches in desensitization: targeted therapies for HLA sensitization[J]. Front Immunol, 2021, 12: 694763. DOI: 10.3389/fimmu.2021.694763.
    [6]
    ZANATTA E, COZZI M, MARSON P, et al. The role of plasma exchange in the management of autoimmune disorders[J]. Br J Haematol, 2019, 186(2): 207-219. DOI: 10.1111/bjh.15903.
    [7]
    SPEER C, KÄLBLE F, NUSSHAG C, et al. Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semiselective immunoadsorption - a retrospective study[J]. Transpl Int, 2019, 32(12): 1286-1296. DOI: 10.1111/tri.13482.
    [8]
    PAVENSKI K, BUCHOLZ M, CHEATLEY PL, et al. The first North American experience using glycosorb immunoadsorption columns for blood group-incompatible kidney transplantation[J]. Can J Kidney Health Dis, 2020, 7: 1-6. DOI: 10.1177/2054358120962586.
    [9]
    MONTAGUD-MARRAHI E, REVUELTA I, CUCCHIARI D, et al. Successful use of nonantigenspecific immunoadsorption with antihuman Ig-columns in kidney graft antibody-mediated rejection[J]. J Clin Apher, 2020, 35(3): 188-199. DOI: 10.1002/jca.21779.
    [10]
    JAMBON F, MERVILLE P, GUIDICELLI G, et al. Efficacy of plasmapheresis and semi-selective immunoadsorption for removal of anti-HLA antibodies[J]. J Clin Apher, 2021, 36(3): 291-298. DOI: 10.1002/jca.21858.
    [11]
    CHAUHAN K, MEHTA AA. Rituximab in kidney disease and transplant[J]. Animal Model Exp Med, 2019, 2(2): 76-82. DOI: 10.1002/ame2.12064.
    [12]
    SOOD P, HARIHARAN S. Anti-CD20 blocker rituximab in kidney transplantation[J]. Transplantation, 2018, 102(1): 44-58. DOI: 10.1097/TP.0000000000001849.
    [13]
    GENBERG H, HANSSON A, WERNERSON A, et al. Pharmacodynamics of rituximab in kidney allotransplantation[J]. Am J Transplant, 2006, 6(10): 2418-2428. DOI: 10.1111/j.1600-6143.2006.01497.x.
    [14]
    KAEGI C, WUEST B, SCHREINER J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders[J]. Front Immunol, 2019, 10: 1990. DOI: 10.3389/fimmu.2019.01990.
    [15]
    GALEOTTI C, KAVERI SV, BAYRY J. IVIG-mediated effector functions in autoimmune and inflammatory diseases[J]. Int Immunol, 2017, 29(11): 491-498. DOI: 10.1093/intimm/dxx039.
    [16]
    PERROTTET N, FERNÁNDEZ-RUIZ M, BINET I, et al. Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: a nationwide cohort study[J]. PLoS One, 2021, 16(4): e0250829. DOI: 10.1371/journal.pone.0250829.
    [17]
    MADDUR MS, STEPHEN-VICTOR E, DAS M, et al. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy[J]. J Neuroinflammation, 2017, 14(1): 58. DOI: 10.1186/s12974-017-0818-5.
    [18]
    STEGALL MD, GLOOR J, WINTERS JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody[J]. Am J Transplant, 2006, 6(2): 346-351. DOI: 10.1111/j.1600-6143.2005.01178.x.
    [19]
    ABU JAWDEH BG, CUFFY MC, ALLOWAY RR, et al. Desensitization in kidney transplantation: review and future perspectives[J]. Clin Transplant, 2014, 28(4): 494- 507. DOI: 10.1111/ctr.12335.
    [20]
    COLLIN M, BJÖRCK L. Toward clinical use of the IgG specific enzymes IdeS and EndoS against antibodymediated diseases[J]. Methods Mol Biol, 2017, 1535: 339- 351. DOI: 10.1007/978-1-4939-6673-8_23.
    [21]
    LORANT T, BENGTSSON M, EICH T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients[J]. Am J Transplant, 2018, 18(11): 2752-2762. DOI: 10.1111/ajt.14733.
    [22]
    KJELLMAN C, MALDONADO AQ, SJÖHOLM K, et al. Outcomes at 3 years post-transplant in imlifidasedesensitized kidney transplant patients[J]. Am J Transplant, 2021, DOI: 10.1111/ajt.16754[Epubaheadofprint].
    [23]
    SLATINSKA J, SLAVCEV A, HONSOVA E, et al. Efficacy and safety of bortezomib treatment for refractory acute antibody-mediated rejection-a pilot study[J]. HLA, 2018, 92(Suppl 2): 47-50. DOI: 10.1111/tan.13387.
    [24]
    PEARL MH, NAYAK AB, ETTENGER RB, et al. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection[J]. Pediatr Nephrol, 2016, 31(8): 1341-1348. DOI: 10.1007/s00467-016-3319-3.
    [25]
    WOODLE ES, SHIELDS AR, EJAZ NS, et al. Prospective iterative trial of proteasome inhibitor-based desensitization[J]. Am J Transplant, 2015, 15(1): 101-118. DOI: 10.1111/ajt.13050.
    [26]
    JEONG JC, JAMBALDORJ E, KWON HY, et al. Desensitization using bortezomib and highdose immunoglobulin increases rate of deceased donor kidney transplantation[J]. Medicine (Baltimore), 2016, 95(5): e2635. DOI: 10.1097/MD.0000000000002635.
    [27]
    ESKANDARY F, REGELE H, BAUMANN L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection[J]. J Am Soc Nephrol, 2018, 29(2): 591-605. DOI: 10.1681/ASN.2017070818.
    [28]
    MORENO GONZALES MA, GANDHI MJ, SCHINSTOCK CA, et al. 32 doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody[J]. Transplantation, 2017, 101(6): 1222-1227. DOI: 10.1097/TP.0000000000001330.
    [29]
    STEGALL MD, DIWAN T, RAGHAVAIAH S, et al. Terminal complement inhibition decreases antibodymediated rejection in sensitized renal transplant recipients[J]. Am J Transplant, 2011, 11(11): 2405-2413. DOI: 10.1111/j.1600-6143.2011.03757.x.
    [30]
    MARKS WH, MAMODE N, MONTGOMERY RA, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial[J]. Am J Transplant, 2019, 19(10): 2876- 2888. DOI: 10.1111/ajt.15364.
    [31]
    JORDAN SC, CHOI J, KIM I, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade[J]. Transplantation, 2017, 101(1): 32-44. DOI: 10.1097/TP.0000000000001452.
    [32]
    JORDAN SC, AMMERMAN N, CHOI J, et al. Interleukin-6: an important mediator of allograft injury[J]. Transplantation, 2020, 104(12): 2497-2506. DOI: 10.1097/TP.0000000000003249.
    [33]
    VO AA, CHOI J, KIM I, et al. A phase I/Ⅱ trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients[J]. Transplantation, 2015, 99(11): 2356- 2363. DOI: 10.1097/TP.0000000000000741.
    [34]
    ORANDI BJ, LUO X, MASSIE AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors[J]. N Engl J Med, 2016, 374(10): 940-950. DOI: 10.1056/NEJMoa1508380.
    [35]
    MANOOK M, KOESER L, AHMED Z, et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis[J]. Lancet, 2017, 389(10070): 727-734. DOI: 10.1016/S0140-6736(16)31595-1.
    [36]
    CLAYTON PA, COATES PT. Are sensitized patients better off with a desensitization transplant or waiting on dialysis?[J]. Kidney Int, 2017, 91(6): 1266-1268. DOI: 10.1016/j.kint.2017.04.004.
    [37]
    KAHWAJI J, SINHA A, TOYODA M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin[J]. Clin J Am Soc Nephrol, 2011, 6(12): 2894-2900. DOI: 10.2215/CJN.03710411.
    [38]
    KO EJ, YU JH, YANG CW, et al. Clinical outcomes of ABO- and HLA-incompatible kidney transplantation: a nationwide cohort study[J]. Transpl Int, 2017, 30(12): 1215-1225. DOI: 10.1111/tri.12979.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (621) PDF downloads(190) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return